10x Genomics
274 hedge funds and large institutions have $996M invested in 10x Genomics in 2025 Q1 according to their latest regulatory filings, with 47 funds opening new positions, 109 increasing their positions, 74 reducing their positions, and 45 closing their positions.
81% more call options, than puts
Call options by funds: $2.66M | Put options by funds: $1.47M
47% more repeat investments, than reductions
Existing positions increased: 109 | Existing positions reduced: 74
7.63% more ownership
Funds ownership: 97.78% → 105.41% (+7.6%)
4% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 45
0% more funds holding
Funds holding: 273 → 274 (+1)
34% less capital invested
Capital invested by funds: $1.5B → $996M (-$507M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
+$62.9M |
| 2 |
Millennium Management
New York
|
+$55.3M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$25.4M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$14.3M |
| 5 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
+$12.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$44.9M |
| 2 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
-$26.5M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$19.3M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$16.8M |
| 5 |
Morgan Stanley
New York
|
-$14.5M |
TXG Hedge Fund Activity: Q1 2025 in Review
274 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q1 2025, worth a combined $996M — down 34% from $1.5B a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new TXG positions and 45 closed out — a net gain of 2 holders — while 109 added to existing stakes and 74 trimmed.
The largest buyer was UBS AM, adding an estimated $62.9M. The largest seller was Fidelity Investments, cutting an estimated $44.9M.
- 274 institutional investors held 10x Genomics (TXG) as of Q1 2025, up from 273 in Q4 2024.
- Funds reported $996M of 10x Genomics stock for Q1 2025, down 34% quarter-over-quarter.
- 47 funds opened new 10x Genomics positions in Q1 2025 and 45 closed out, a net change of +2 holders.
- The largest 10x Genomics buyer in Q1 2025 was UBS AM, an estimated $62.9M added.
- The largest 10x Genomics seller in Q1 2025 was Fidelity Investments, an estimated $44.9M sold.
Based on aggregated 13F filings for Q1 2025.